Dr. David Miklos, MD, PhD
Claim this profileStanford University
Studies Lymphoma
Studies Non-Hodgkin's Lymphoma
10 reported clinical trials
16 drugs studied
Area of expertise
1Lymphoma
CD19 positive
BCL2 positive
BCL6 positive
2Non-Hodgkin's Lymphoma
CD19 positive
BCL2 positive
BCL6 positive
Affiliated Hospitals
Clinical Trials David Miklos, MD, PhD is currently running
18F-F-AraG PET Imaging
for Lymphoma
This is a pilot study in adult subjects with aggressive B-cell lymphoma who will receive commercial or research CAR T cell therapy as anticancer treatment.
Recruiting1 award Phase 2
CAR T-Cell Therapy
for Non-Hodgkin's Lymphoma
A Phase 1/2 Study of bbT369, a dual targeting CAR T cell drug product with a gene edit, in Relapsed and/or Refractory B cell Non-Hodgkin's Lymphoma.
Recruiting1 award Phase 1 & 2
More about David Miklos, MD, PhD
Clinical Trial Related7 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments David Miklos, MD, PhD has experience with
- Cyclophosphamide
- Obinutuzumab
- CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells
- NKTR-255
- Fludarabine Phosphate
- Axicabtagene Ciloleucel
Breakdown of trials David Miklos, MD, PhD has run
Lymphoma
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Lymphoblastic Leukemia-Lymphoma
Acute Lymphoblastic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Miklos, MD, PhD specialize in?
David Miklos, MD, PhD focuses on Lymphoma and Non-Hodgkin's Lymphoma. In particular, much of their work with Lymphoma has involved CD19 positive patients, or patients who are BCL2 positive.
Is David Miklos, MD, PhD currently recruiting for clinical trials?
Yes, David Miklos, MD, PhD is currently recruiting for 7 clinical trials in Palo Alto California. If you're interested in participating, you should apply.
Are there any treatments that David Miklos, MD, PhD has studied deeply?
Yes, David Miklos, MD, PhD has studied treatments such as Cyclophosphamide, Obinutuzumab, CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells.
What is the best way to schedule an appointment with David Miklos, MD, PhD?
Apply for one of the trials that David Miklos, MD, PhD is conducting.
What is the office address of David Miklos, MD, PhD?
The office of David Miklos, MD, PhD is located at: Stanford University, Palo Alto, California 94305 United States. This is the address for their practice at the Stanford University.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.